Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

Participation Deadline: 10/31/2029
Apply Now

Description

Up to 15 participants will receive treatment with olutasidenib 150 mg by mouth twice daily for up to 2 years. Participants will be regularly monitored for toxicities, adverse events, quality of life (QOL), and disease status. Once off treatment, participants will continue to be followed for a maximum of 2 years from date of enrollment for survival endpoints